Jazz returns to Redx, this time for KRAS inhibitorKRAS inhibitor programme

07 Feb 2024
firstwordpharma.com
Drug ApprovalAcquisitionLicense out/in
Jazz Pharmaceuticals added another one of Redx Pharma’s assets to its oncology pipeline, this time paying $10 million upfront for a preclinical KRAS inhibitorKRAS inhibitor programme. The company previously acquired a pan-RAF inhibitor programme from Redx, with the parties later inking a deal to develop drugs against two cancer targets in the MAPK pathway.
“Redx has discovered a number of preclinical KRAS candidates and we plan to leverage our collective oncology development expertise to identify and advance the most promising molecules toward the clinic," remarked Robert Iannone, global head of R&D at Jazz.
Amgen’s Lumakras (sotorasib) became the first KRAS inhibitorKRAS inhibitor to hit the market, although it has struggled commercially, with sales down 2% last year at $280 million. Meanwhile, the FDA recently declined to grant full approval to the drug for patients with KRASG12c-mutated non-small-cell lung cancer after asking for a new confirmatory study.
The companies will collaborate to advance candidates through IND-enabling studies, with Jazz being responsible for all clinical development, regulatory, manufacturing and commercialisation activities. Redx is eligible to receive up to $870 million in milestone payments from Jazz,  as well as tiered, mid-single digit percentage sales royalties.
Meanwhile, Redx CEO Lisa Anson noted that the upfront milestone payment from the agreement with Jazz will extend its cash runway into 2025. The company unsuccessfully tried to merge with Jounce Therapeutics last year, with the latter dropping a proposed deal in favour of an acquisition by Concentra Biosciences.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.